Here’s what you should know:
1. Kansas City, Mo.-based Kansas School of Medicine’s Prashanth Vennalaganti, MD, and colleagues led a multicenter, prospective, randomized tandem center study through 16 U.S. gastroenterology centers.
2. Of 160 high-risk patients, Wats3D detected 29 HGD/EAC cases. The Seattle random forceps biopsy only detected seven.
3. Researchers concluded the Seattle random forceps biopsy was severely limited, and although Wats3D takes a “few extra minutes” the results were valuable.
4 Incoming Chief of Gastroenterology at New York City-based Mount Sinai West Michael Smith, MD, said in a release, “I can think of very few high impact studies in the field of Barrett’s esophagus that should change how gastroenterologists, both community-based and academic, care for their patients, and this study is one of them. These robust data demonstrate we have a tool that markedly improves our ability to detect dysplasia and cancer within Barrett’s well beyond the error-prone Seattle protocol.”
More articles on gastroenterology:
GI center to know: Center for Colonoscopy Excellence
Metro Health adds seven gastroenterologists — 3 key notes
GI leader to know: Dr. Frank Farrell of Center for Colonoscopy Excellence
